10X Genomics (TXG) Stock Rises 4% on Cleveland Clinic Bladder Cancer Collaboration
10X Genomics shares gained 3.8% following news of a multi-year research partnership with Cleveland Clinic focused on bladder cancer biomarkers. The collaboration will leverage TXG's single-cell analysis platforms to study tumor microenvironment responses to emerging antibody-drug conjugate therapies.
While insiders have sold $1.8 million in shares recently, the market reacted positively to the potential long-term implications of this academic-commercial partnership in precision oncology.
Log in to Reply
Log in to comment your thoughtsComments
Related Articles
|Square
Get the BTCC app to start your crypto journey
Get started today Scan to join our 100M+ users